Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Debt to Equity (2016 - 2025)

Bioadaptives' Debt to Equity history spans 8 years, with the latest figure at -$0.82 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 13.46% to -$0.82 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.82, a 13.46% decrease, with the full-year FY2025 number at -$0.82, down 13.46% from a year prior.
  • Debt to Equity hit -$0.82 in Q4 2025 for Bioadaptives, down from -$0.66 in the prior quarter.
  • Over the last five years, Debt to Equity for BDPT hit a ceiling of -$0.47 in Q4 2022 and a floor of -$0.82 in Q4 2025.
  • Historically, Debt to Equity has averaged -$0.6 across 5 years, with a median of -$0.6 in 2021.
  • Biggest five-year swings in Debt to Equity: tumbled 25371.99% in 2021 and later increased 25.85% in 2022.
  • Tracing BDPT's Debt to Equity over 5 years: stood at -$0.51 in 2021, then increased by 7.15% to -$0.47 in 2022, then decreased by 25.5% to -$0.59 in 2023, then dropped by 21.15% to -$0.72 in 2024, then dropped by 13.46% to -$0.82 in 2025.
  • Business Quant data shows Debt to Equity for BDPT at -$0.82 in Q4 2025, -$0.66 in Q3 2025, and -$0.7 in Q2 2025.